Catherine Gutierrez Moore, M.D.,Ph.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2023 | 1640 | 0.930 |
Why?
|
| Ikaros Transcription Factor | 1 | 2021 | 232 | 0.330 |
Why?
|
| Craniopharyngioma | 1 | 2021 | 277 | 0.320 |
Why?
|
| Quinazolinones | 1 | 2019 | 221 | 0.300 |
Why?
|
| Purines | 1 | 2019 | 605 | 0.270 |
Why?
|
| Receptors, LDL | 1 | 2017 | 488 | 0.240 |
Why?
|
| Pituitary Neoplasms | 1 | 2021 | 1324 | 0.210 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1793 | 0.210 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 1248 | 0.200 |
Why?
|
| Government Regulation | 1 | 2016 | 524 | 0.200 |
Why?
|
| Lysosomes | 1 | 2017 | 923 | 0.190 |
Why?
|
| Adenoma | 1 | 2021 | 2160 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 934 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2019 | 1975 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2019 | 2007 | 0.160 |
Why?
|
| Tuberous Sclerosis | 1 | 2017 | 1030 | 0.160 |
Why?
|
| Mutation | 4 | 2023 | 30045 | 0.160 |
Why?
|
| Clone Cells | 2 | 2022 | 1659 | 0.150 |
Why?
|
| Cholesterol | 1 | 2017 | 2902 | 0.150 |
Why?
|
| Astrocytoma | 1 | 2022 | 775 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4764 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2019 | 3027 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7595 | 0.140 |
Why?
|
| Receptors, Notch | 1 | 2021 | 743 | 0.140 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3702 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 1923 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2017 | 4936 | 0.110 |
Why?
|
| Models, Biological | 1 | 2019 | 9469 | 0.110 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 1827 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 2538 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 13637 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2021 | 545 | 0.070 |
Why?
|
| Glioma | 1 | 2022 | 3455 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2022 | 3482 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 7874 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5305 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 651 | 0.070 |
Why?
|
| World Health Organization | 1 | 2021 | 1316 | 0.060 |
Why?
|
| Cell Line | 2 | 2021 | 15605 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 6339 | 0.060 |
Why?
|
| Genomics | 2 | 2021 | 5820 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2023 | 2448 | 0.060 |
Why?
|
| Adenine | 1 | 2019 | 987 | 0.060 |
Why?
|
| Neoplasms | 1 | 2022 | 22164 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 6935 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 495 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2021 | 2488 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18247 | 0.050 |
Why?
|
| Daptomycin | 1 | 2021 | 71 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 9031 | 0.050 |
Why?
|
| Piperidines | 1 | 2019 | 1656 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 1668 | 0.050 |
Why?
|
| Humans | 12 | 2023 | 761423 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2824 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2023 | 428 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 716 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2449 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 6766 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 2871 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2626 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 938 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3798 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 3321 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6132 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3602 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22163 | 0.030 |
Why?
|
| United States | 3 | 2023 | 72339 | 0.020 |
Why?
|
| Prognosis | 2 | 2023 | 29620 | 0.020 |
Why?
|
| Male | 4 | 2021 | 360736 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12688 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 81509 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 23441 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12720 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14409 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10441 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15717 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 9488 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8545 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 220826 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 168441 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 7409 | 0.010 |
Why?
|
| Female | 3 | 2023 | 392581 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 59207 | 0.010 |
Why?
|
| Child | 1 | 2022 | 80162 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 88313 | 0.010 |
Why?
|
| Adult | 1 | 2023 | 221148 | 0.000 |
Why?
|